Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.125
+0.005 (0.16%)
May 18, 2026, 9:42 AM EDT - Market open
Esperion Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Esperion Therapeutics stock has a consensus rating of "Hold" and an average price target of $3.19. The average 1-year stock price forecast is 2.08% higher than the current stock price, while the lowest is $3.16 (+1.12%) and the highest is $3.28 (+4.96%).
Price Target: $3.19 (+2.08%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Buy | 4 | 4 | 4 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 4, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $3.16 | Strong Buy → Hold | Downgrades | $3.16 | +1.12% | May 1, 2026 |
| Citizens | Citizens | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +60.00% | Mar 13, 2026 |
| Needham | Needham | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +60.00% | Mar 3, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $9 | Buy | Initiates | $9 | +188.00% | Nov 25, 2025 |
Financial Forecast
Revenue This Year
386.35M
from 403.14M
Decreased by -4.16%
Revenue Next Year
446.13M
from 386.35M
Increased by 15.47%
EPS This Year
0.05
from -0.11
EPS Next Year
0.27
from 0.05
Increased by 422.43%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 461.3M | 572.5M | ||||||
| Avg | 386.4M | 446.1M | ||||||
| Low | 331.0M | 292.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 14.4% | 48.2% | ||||||
| Avg | -4.2% | 15.5% | ||||||
| Low | -17.9% | -24.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.59 | 0.49 | ||||||
| Avg | 0.05 | 0.27 | ||||||
| Low | -0.26 | 0.09 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 846.1% | ||||||
| Avg | - | 422.4% | ||||||
| Low | - | 69.1% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.